Benzyl Alcohol

Benzyl Alcohol

SCHEMBL872990

CCCC(O)Cl.OCc1ccccc1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
POLB P06746 1/20 0.40
AOC3 Q16853 2/20 0.40
CSNK1E P49674 1/20 0.39
TRPA1 O75762 2/20 0.39
LTA4H P09960 1/20 0.38
TP53 P04637 1/20 0.38
LMNA P02545 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
CNR2 P34972 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
PRKCA P17252 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzyl Alcohol SCHEMBL10779840 0.84 TSHR (0.58) TSHRPOLBAOC3CSNK1ETRPA1
Phenol SCHEMBL4386880 0.80 TDP1 (0.46) POLBAOC3LMNASLC6A2SLC6A3
Benzyl Alcohol SCHEMBL3088175 0.79 TSHR (0.70) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL8057636 0.79 TSHR (0.78) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL109525 0.79 TSHR (0.78) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL11807282 0.77 TSHR (0.74) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL4915528 0.77 TSHR (0.74) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL7114015 0.77 TSHR (0.74) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL28108812 0.76 TSHR (0.82) TSHRTRPA1LTA4HTP53PPARG
Benzyl Alcohol SCHEMBL540993 0.76 TSHR (0.82) TSHRTRPA1LTA4HTP53PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229636-B1 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery NASTECH PHARMACEUTICAL COMPANY INC. (US) 2007-06-12 US claimed
US-20200317783-A1 BISPECIFIC ANTIBODY ONO PHARMACEUTICAL CO., LTD. (JP) 2020-10-08 US disclosed
US-8883504-B2 Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line ASAHI KASEI KABUSHIKI KAISHA (JP) 2014-11-11 US disclosed
EP-1997902-B1 SCREENING METHOD UNIV HIROSHIMA (JP) 2013-09-18 EP disclosed
US-8329420-B2 Screening method for a substance that binds to an intracellular region of TLR4 HIROSHIMA UNIVERSITY (JP) 2012-12-11 US disclosed
US-20120077856-A1 PHARMACEUTICAL PRODUCT TAKEDA PHARMACEUTICAL COMPANY LIMITED 2012-03-29 US disclosed
EP-2366389-A1 Severe sepsis preventive therapeutic agent Takeda Pharmaceutical Company Limited (JP) 2011-09-21 EP disclosed
US-20110184034-A1 Severe sepsis preventive therapeutic agent TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-28 US disclosed
EP-2260869-A2 Pharmaceutical product Takeda Pharmaceutical Company Limited (JP) 2010-12-15 EP disclosed
US-20090317833-A1 Screening Method HIROSHIMA UNIVERSITY (JP) 2009-12-24 US disclosed
US-20090062355-A1 Pharmaceutical Product TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-03-05 US disclosed
EP-2018855-A1 PHARMACEUTICAL AGENT Takeda Pharmaceutical Company Limited (JP) 2009-01-28 EP disclosed
EP-2018872-A1 PHARMACEUTICAL PRODUCT Takeda Pharmaceutical Company Limited (JP) 2009-01-28 EP disclosed
EP-1997902-A1 SCREENING METHOD Hiroshima University (JP) 2008-12-03 EP disclosed
US-20060058288-A1 Severe sepsis preventive therapeutic agent TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2006-03-16 US disclosed
EP-1495756-A1 SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT Takeda Chemical Industries, Ltd. (JP) 2005-01-12 EP disclosed
US-20040009168-A1 Multidose antibody formulation PROTEIN DESIGN LABS, INC. 2004-01-15 US disclosed
US-6180621-B1 ADMINISTERING TO WARM-BLOODED ANIMALS FOR TREATMENT AND PREVENTION OF INFECTIOUS DISEASES CAUSED BY HELICOBACTER PYLORI SANKYO COMPANY, LIMITED (JP) 2001-01-30 US disclosed
US-5021439-A Senile dementia and memory dysfunction TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-06-04 US disclosed
US-4912215-A Cyclic structure with a secondary amide in ring YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1990-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062355-A1 Pharmaceutical Product ATF1, ATF4, TLR8 TSHR 3079/4885POLB 4373/4885AOC3 4277/4885
US-20060058288-A1 Severe sepsis preventive therapeutic agent TLR1, TLR5, TLR4 TSHR 2785/4885POLB 4084/4885AOC3 3542/4885
US-20110184034-A1 Severe sepsis preventive therapeutic agent TLR1, TLR5, TLR4 TSHR 2755/4885POLB 4122/4885AOC3 3551/4885
US-20120077856-A1 PHARMACEUTICAL PRODUCT ATF1, ATF4, TLR8 TSHR 3079/4885POLB 4373/4885AOC3 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.